NEW YORK (360Dx) – Metafora Biosystems recently received support from the French government to undertake a study of its MetaGlut1 test for diagnosing glucose transporter 1 (Glut1) deficiency syndrome.
Set to take place over the next 30 months and to involve 3,000 patients across 60 centers in France, the effort could lead to Metafora's flow cytometry-based assay becoming the standard of care for diagnosing the disease in France.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
